Analyst Reco. Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2025-12-08 pm EST			5-day change	1st Jan Change
997.59 ^USD	-1.26%		-5.70%	+29.22%

Dec. 08	Health Care Down Amid Intensified Obesity-Drug Competition - Health Care Roundup	DJ
Dec. 08	Eli Lilly declares Q1 2026 dividend of $1.73 per share	RE

Analyst Reco.

Goldman Sachs Adjusts Price Target on Eli Lilly and Co. to $1,145 From $951, Maintains Buy Rating	Dec. 08	MT
BMO Capital Adjusts PT on Eli Lilly and Company to $1,200 From $1,100, Maintains Outperform Rating	Dec. 04	MT
Wolfe Research Adjusts PT on Eli Lilly and Company to $1,250 From $1,050, Maintains Outperform Rating	Dec. 03	MT
Guggenheim Adjusts Price Target on Eli Lilly and Company to $1,163 From $1,036, Maintains Buy Rating	Dec. 03	MT
Eli Lilly Price Target, Earnings Estimates Up as Berenberg Highlights Strong Q3, Upcoming Catalysts	Dec. 02	MT
Berenberg Adjusts Price Target on Eli Lilly and Co. to $950 From $830, Maintains Hold Rating	Dec. 02	MT
AlphaValue/Baader Europe Notes 'Extremely Adverse' Investor Sentiment on Novo Nordisk; Price Target Down	Nov. 25	MT
Sector Update: Health Care Stocks Advance Late Afternoon	Nov. 24	MT
Sector Update: Health Care Stocks Advance in Afternoon Trading	Nov. 24	MT
Sector Update: Health Care	Nov. 24	MT
Eli Lilly Benefits From 'Broadening' GLP-1 Market, Morgan Stanley Says	Nov. 24	MT
Bernstein Adjusts PT on Eli Lilly and Co. to $1,300 From $1,100, Maintains Outperform Rating	Nov. 24	MT
Morgan Stanley Adjusts PT on Eli Lilly and Co. to $1,290 From $1,171, Maintains Overweight Rating	Nov. 24	MT
Truist Raises Price Target on Eli Lilly to $1,182 From $1,038, Keeps Buy Rating	Nov. 19	MT
Truist Raises Price Target on Eli Lilly to $1,182 From $$1,038, Keeps Buy Rating	Nov. 19	MT
JPMorgan Adjusts PT on Eli Lilly and Co. to $1,150 From $1,050, Maintains Overweight Rating	Nov. 18	MT
Scotiabank Initiates Eli Lilly and Co. at Sector Outperform With $1,165 Price Target	Nov. 13	MT
Morgan Stanley Adjusts PT on Eli Lilly and Co. to $1,171 From $1,090, Maintains Overweight Rating	Nov. 13	MT
CICC Adjusts Price Target on Eli Lilly and Co. to $1,060 From $801, Maintains Neutral Rating	Nov. 13	MT
Analyst recommendations: AMD, Dollar Tree, Comcast, Nike, Cisco…	Nov. 13
Citigroup Adjusts Price Target on Eli Lilly and Co. to $1,500 From $1,250, Maintains Buy Rating	Nov. 12	MT
North American Morning Briefing : Stock Futures Slip Despite Shutdown Resolution Hopes -2-	Nov. 11	DJ
Sector Update: Health Care Stocks Advance Late Afternoon	Nov. 10	MT
Sector Update: Health Care	Nov. 10	MT
Eli Lilly Shares Rise After Leerink Partners Upgrade	Nov. 10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Lilly Cuts Prices for Cash Buyers of Weight-Loss Drug Zepbound

December 01, 2025 at 10:39 am EST

Is it back to square one for Eli Lilly?

August 07, 2025 at 11:20 am EDT